- Home
- FFWM vs STOK Comparison
FFWM vs STOK Comparison
Compare FFWM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFWM
- STOK
- Stock Information
- Founded
- FFWM 1990
- STOK 2014
- Country
- FFWM United States
- STOK United States
- Employees
- FFWM N/A
- STOK N/A
- Industry
- FFWM Major Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- FFWM Finance
- STOK Health Care
- Exchange
- FFWM Nasdaq
- STOK Nasdaq
- Market Cap
- FFWM 630.9M
- STOK 721.4M
- IPO Year
- FFWM 2014
- STOK 2019
- Fundamental
- Price
- FFWM $6.99
- STOK $11.84
- Analyst Decision
- FFWM Buy
- STOK Strong Buy
- Analyst Count
- FFWM 5
- STOK 7
- Target Price
- FFWM $7.80
- STOK $21.40
- AVG Volume (30 Days)
- FFWM 353.4K
- STOK 562.4K
- Earning Date
- FFWM 01-23-2025
- STOK 11-05-2024
- Dividend Yield
- FFWM 0.29%
- STOK N/A
- EPS Growth
- FFWM N/A
- STOK N/A
- EPS
- FFWM N/A
- STOK N/A
- Revenue
- FFWM $108,182,000.00
- STOK $16,742,999.00
- Revenue This Year
- FFWM N/A
- STOK $103.04
- Revenue Next Year
- FFWM $31.32
- STOK N/A
- P/E Ratio
- FFWM N/A
- STOK N/A
- Revenue Growth
- FFWM N/A
- STOK 81.08
- 52 Week Low
- FFWM $4.84
- STOK $4.09
- 52 Week High
- FFWM $11.47
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- FFWM 37.61
- STOK 41.75
- Support Level
- FFWM $6.94
- STOK $11.80
- Resistance Level
- FFWM $7.42
- STOK $12.58
- Average True Range (ATR)
- FFWM 0.29
- STOK 0.83
- MACD
- FFWM -0.12
- STOK -0.06
- Stochastic Oscillator
- FFWM 7.66
- STOK 8.32
About FFWM First Foundation Inc.
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.